Literature DB >> 8181147

Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats.

M R Tschudi1, L Criscione, D Novosel, K Pfeiffer, T F Lüscher.   

Abstract

BACKGROUND: Coronary artery disease is an important complication of hypertension. Therefore, the effects of antihypertensive therapy on the endothelial nitric oxide (NO)/L-arginine pathway and vascular smooth muscle were studied in left anterior descending coronary arteries of Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR). Angiotensin II (AT1) receptor antagonists CGP 48369 and valsartan, angiotensin-converting enzyme inhibitor benazepril HCl, and calcium antagonist nifedipine were used as antihypertensive agents. METHODS AND
RESULTS: Rings were examined in myograph systems for isometric tension recording. In untreated WKY and SHR rings, acetylcholine (10(-9) to 10(-5) mol/L) but not bradykinin, substance P (both 10(-6) mol/L), or thrombin (1 U/mL) induced comparable endothelium-dependent relaxations. These relaxations were markedly decreased by NG-monomethyl-L-arginine (10(-4) mol/L) and fully prevented by N omega-nitro-L-arginine methyl ester (10(-4) mol/L) or methylene blue (10(-5) mol/L). In vitro treatment of WKY and SHR rings with benazeprilat, CGP 48369, or valsartan (3 x 10(-7) mol/L) did not affect responses to acetylcholine. In SHR, chronic therapy for 8 weeks with benazepril HCl, CGP 48369, valsartan, or nifedipine (each 10 mg.kg-1.d-1 PO) similarly reduced blood pressure and increased endothelium-dependent relaxations to acetylcholine (log shift at IC50, ie, half-maximal inhibition of a preceding contraction, 10-, 8-, 13-, and 13-fold, P < .05 versus control), whereas relaxations to the NO donor 3-morpholino sydnonimine (SIN-1, 10(-9) to 10(-5) mol/L) remained unaffected. In WKY, chronic therapy with nifedipine (10 mg.kg-1.d-1 PO) affected neither blood pressure nor relaxations to acetylcholine or SIN-1.
CONCLUSIONS: In rat coronary arteries, NO is synthesized via the endothelial L-arginine pathway and released after stimulation with acetylcholine. In SHR, chronic antihypertensive therapy with either angiotensin receptor antagonists, an angiotensin-converting enzyme inhibitor, or a calcium antagonist specifically increased the normal endothelium-dependent relaxations to acetylcholine, probably because of their blood pressure-lowering effects, whereas the responsiveness of vascular smooth muscle to NO remained unaffected.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8181147     DOI: 10.1161/01.cir.89.5.2212

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

Review 1.  Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.

Authors:  Stefano Taddei; Agostino Virdis; Lorenzo Ghiadoni; Isabella Sudano; Antonio Salvetti
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy.

Authors:  J R Martens; P Y Reaves; D Lu; M J Katovich; K H Berecek; S P Bishop; M K Raizada; C H Gelband
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 3.  Antihypertensive drugs and reversing of endothelial dysfunction in hypertension.

Authors:  S Taddei; A Virdis; L Ghiadoni; I Sudano; A Salvetti
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

4.  Synergistic interaction between enalapril, L-arginine and tetrahydrobiopterin in smooth muscle cell apoptosis and aortic remodeling induction in SHR.

Authors:  Shant Der Sarkissian; Eve-Lyne Marchand; David Duguay; Denis deBlois
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

Review 5.  Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.

Authors:  T F Lüscher; R R Wenzel; P Moreau; H Takase
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

Review 6.  Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors.

Authors:  Michel Félétou; Tony J Verbeuren; Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2009-01-19       Impact factor: 8.739

7.  Antihypertensive treatment differentially affects vascular sphingolipid biology in spontaneously hypertensive rats.

Authors:  Léon J A Spijkers; Ben J A Janssen; Jelly Nelissen; Merlijn J P M T Meens; Dayanjan Wijesinghe; Charles E Chalfant; Jo G R De Mey; Astrid E Alewijnse; Stephan L M Peters
Journal:  PLoS One       Date:  2011-12-15       Impact factor: 3.240

8.  Preclinical Evaluation of the Antihypertensive Effect of an Aqueous Extract of Anogeissus leiocarpa (DC) Guill et Perr. Bark of Trunk in L-NAME-Induced Hypertensive Rat.

Authors:  Lazare Belemnaba; Mathieu Nitiéma; Sylvain Ilboudo; Gueswindé Geoffroy Ouédraogo; Noufou Ouédraogo; Mohamed Bonewendé Belemlilga; Souleymane Compaoré; Salfo Ouédraogo; Sylvin Ouédraogo
Journal:  J Exp Pharmacol       Date:  2021-08-07

Review 9.  Nitric oxide and coronary vascular endothelium adaptations in hypertension.

Authors:  Andrew S Levy; Justin C S Chung; Jeffrey T Kroetsch; James W E Rush
Journal:  Vasc Health Risk Manag       Date:  2009-12-29

10.  A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study.

Authors:  Thomas Felix Lüscher; Michael Pieper; Michael Tendera; Mathy Vrolix; Wolfgang Rutsch; Frank van den Branden; Robert Gil; Karl-Otto Bischoff; Michael Haude; Dieter Fischer; Thomas Meinertz; Thomas Münzel
Journal:  Eur Heart J       Date:  2009-05-27       Impact factor: 29.983

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.